Table 3.
Test Results and Demographic and Clinical Information for Patients With Serially Collected Cerebrospinal Fluid
| Patient No. | Sex | Age, y | LP Datea | PCR Result | Culture | WBC/mL | BDG, pg/mL (± SD)b | Clinical Outcome |
|---|---|---|---|---|---|---|---|---|
| Patient 1 | F | 42 | 5-Oct-12 | Er | Negative | 2507 | N/P | Multiple strokes, deceased |
| 7-Nov-12 | Negative | Negative | 1330 | >500 | ||||
| 10-Dec-12 | Negative | Negative | 104 | N/P | ||||
| 15-Jan-13 | Negative | Negative | 57 | >500 | ||||
| Patient 2 | F | 64 | 7-Oct-12 | Negative | Negative | 2576 | >500 | Relapse meningitis, on retreatment, stable |
| 7-Nov-12 | Negative | Negative | 177 | >500 | ||||
| 6-Feb-13 | Negative | Negative | 0 | >500 | ||||
| 16-May-13 | Cc | Negative | 513 | >500 | ||||
| 30-May-13 | Negative | Negative | 145 | >500 | ||||
| Patient 3c | M | 80 | 4-Oct-12 | Negative | Negative | 119 | >500 | Relapse meningitis, on treatment, stable |
| 17-Oct-12 | Negative | Negative | 63 | >500 | ||||
| 30-Nov-12 | Negative | Negative | 9 | 488 ± 11 | ||||
| 11-Jan-13 | Negative | Negative | 5 | 246 ± 75 | ||||
| 11-Mar-13 | Er | Negative | 2075 | >500 | ||||
| Patient 4 | F | 77 | 9-Oct-12 | Er | Negative | 2550 | >500 | Relapse soft tissue phlegmon, on retreatment, stable |
| 13-Oct-12 | Negative | Cc | 999 | N/P | ||||
| 8-Nov-12 | Negative | Negative | 34 | >500 | ||||
| 5-Dec-12 | Negative | Negative | 0 | >500 | ||||
| Patient 5 | M | 72 | 5-Oct-12 | Er | Negative | 1989 | >500 | Completed treatment, asymptomatic, stable |
| 19-Dec-12 | Negative | Negative | 5 | >500 | ||||
| 13-Feb-13 | Negative | Negative | 2 | 387 ± 33 | ||||
| 3-Apr-13 | Negative | Negative | 7 | 218 ± 4 | ||||
| Patient 6 | M | 69 | 4-Oct-12 | Negative | Negative | 664 | >500 | Completed treatment, asymptomatic, stable |
| 5-Dec-12 | Negative | Negative | 14 | >500 | ||||
| 6-Mar-13 | Negative | Negative | 0 | 383 ± 32 | ||||
| Patient 7 | F | 64 | 11-Oct-12 | Er | Negative | 3996 | >500 | Completed treatment, asymptomatic, stable |
| 25-Oct-12 | Negative | Negative | 43 | N/P | ||||
| 2-Jan-13 | Negative | Negative | 7 | >500 | ||||
| 6-Feb-13 | Negative | Negative | 5 | 438 ± 23 | ||||
| 8-Apr-13 | Negative | Negative | 5 | 408 ± 32 | ||||
| 15-Jul-13 | Negative | Negative | 3 | 252 ± 103 | ||||
| Patient 8 | M | 44 | 6-Oct-12 | Negative | Negative | 602 | N/P | Completed treatment, asymptomatic, stable |
| 28-Nov-12 | Negative | Negative | 85 | >500 | ||||
| 4-Jan-13 | Negative | Negative | 7 | >500 | ||||
| 25-Feb-13 | Negative | Negative | 14 | 391 ± 14 | ||||
| 1-Apr-13 | Negative | Negative | 5 | 457 ± 61 | ||||
| 6-May-13 | Negative | Negative | 8 | <32 | ||||
| Patient 9 | F | 75 | 5-Nov-12 | N/P | Er | 529 | N/P | Completed treatment, asymptomatic, stable |
| 22-Oct-12 | Negative | Negative | 3106 | >500 | ||||
| 23-Nov-12 | Negative | Negative | 10 | 412 ± 3 | ||||
| 1-Feb-13 | Negative | Negative | 14 | 238 ± 2 | ||||
| 8-Mar-13 | Negative | Negative | 2 | 120 ± 25 | ||||
| Patient 10 | F | 84 | 4-Oct-12 | Negative | Negative | 2676 | >500 | Continues on treatment (8 mo), stable |
| 21-Nov-12 | Negative | Negative | 66 | >500 | ||||
| 1-Mar-13 | Negative | Negative | 17 | >500 | ||||
| 5-Apr-13 | Negative | En | 157 | 427 ± 35 | ||||
| 26-Apr-13 | Negative | Negative | 48 | 240 ± 14 | ||||
| 28-May-13 | Negative | Negative | 43 | <32 | ||||
| Patient 11 | M | 65 | 4-Oct-12 | Er | Negative | 1828 | >500 | Completed treatment, asymptomatic, stable |
| 2-Nov-12 | Negative | Negative | 71 | 235 ± 17 | ||||
| 9-Jan-13 | Negative | Negative | 2 | <32 | ||||
| 7-Feb-13 | Negative | Negative | 0 | 41 ± 9 | ||||
| 8-May-13 | Negative | Negative | 0 | <32 | ||||
| Patient 12 | F | 58 | 29-Sep-12 | Negative | Cc | 9080 | >500 | Completed treatment, asymptomatic, stable |
| 22-Oct-12 | Negative | Negative | 173 | N/P | ||||
| 21-Dec-12 | Negative | Negative | 2 | 112 ± 5 | ||||
| 21-Mar-13 | Negative | Negative | 7 | 55 | ||||
| Patient 13 | M | 77 | 8-Oct-12 | Negative | Negative | 1530 | >500 | Completed treatment, asymptomatic, stable |
| 9-Nov-12 | Negative | Negative | 6373 | >500 | ||||
| 3-Jan-13 | Negative | Negative | 65 | >500 | ||||
| 5-Feb-13 | Negative | Negative | 5 | 104 ± 0 | ||||
| 5-Apr-13 | Negative | Negative | 17 | 129 ± 21 | ||||
| 20-Apr-13 | Negative | Negative | 7 | 45 ± 0 | ||||
| Patient 14 | M | 50 | 4-Oct-12 | Er | Er | 830 | >500 | Continues on treatment (8 mo), stable |
| 8-Nov-12 | Negative | Negative | 418 | >500 | ||||
| 18-Dec-12 | Negative | Negative | 121 | >500 | ||||
| 12-Mar-13 | Negative | Negative | 50 | 32 ± 61 | ||||
| 3-Jun-13 | Negative | Negative | 16 | 335 | ||||
| 5-Aug-13 | Negative | Negative | 157 | 385 ± 25 | ||||
| Patient 15 | M | 70 | 5-Oct-12 | Negative | Negative | 2610 | >500 | Completed treatment, asymptomatic, stable |
| 8-Nov-12 | Negative | Negative | 7 | 297 ± 20 | ||||
| 12-Dec-12 | Negative | Negative | 2 | 241 ± 18 | ||||
| 6-Feb-13 | Negative | Negative | 0 | 69 ± 12 | ||||
| 5-Apr-13 | Negative | Negative | 0 | 123 ± 2 | ||||
| Patient 16 | M | 61 | 8-Oct-12 | Negative | Negative | 280 | >500 | Completed treatment, asymptomatic, stable |
| 12-Nov-12 | Negative | Negative | 52 | 385 ± 75 | ||||
| 5-Dec-12 | Negative | Negative | 0 | 41 ± 1 | ||||
| 4-Mar-13 | Negative | Negative | 0 | <32 | ||||
| 10-May-13 | Negative | Negative | 0 | <32 | ||||
| Patient 17 | F | 55 | 24-Oct-12 | Er | Negative | 48 | >500 | Completed treatment asymptomatic stable |
| 28-Nov-12 | Negative | En | 954 | >500 | ||||
| 23-Jan-13 | Negative | Negative | 0 | 110 ± 4 | ||||
| 1-Apr-13 | Negative | Negative | 2 | 50 ± 4 | ||||
| Patient 18 | F | 92 | 15-Oct-12 | Negative | Negative | 28 | 486 ± 124 | Completed treatment, asymptomatic, stable |
| 19-Nov-12 | Negative | Negative | 2 | 426 ± 269 | ||||
| 22-Jan-13 | Negative | Negative | 5 | 278 ± 11 | ||||
| 1-May-13 | Negative | Negative | 2 | 266 ± 14 | ||||
| Patient 19 | M | 16 | 29-Oct-12 | Er | Negative | 710 | 450 ± 14 | Completed treatment, asymptomatic, stable |
| 12-Dec-12 | Negative | Negative | 90 | >500 | ||||
| 21-Jan-13 | Negative | Negative | 12 | 171 ± 52 | ||||
| 17-May-13 | Negative | Negative | 6 | <32 | ||||
| Patient 20 | F | 63 | 11-Oct-12 | Negative | Negative | 777 | >500 | Completed treatment asymptomatic stable |
| 30-Oct-12 | Negative | Negative | 475 | >500 | ||||
| 18-Feb-13 | Negative | Negative | 33 | 280 ± 8 | ||||
| 15-May-13 | Negative | Negative | 5 | 296 ± 18 |
Abbreviations: BDG, (1–3)-β-d-glucan; Cc, Cladosporium cladosporioides; En, Epicoccum nigrum; Er, Exserohilum rostratum; LP, lumbar puncture; N/P, not performed; PCR, polymerase chain reaction; WBC, white blood cell.
a Only LPs with PCR, culture, and/or BDG results are included.
b Mean and standard deviation (SD) of the 3 readings.
c Reference [17].